Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for <i>Clostridioides difficile</i> Infection and Associated Clinical Outcomes.

We also observed an absolute difference in the 4-week CDI recurrence rates (−8.4% in initial CDI episodes [20.6% for fidaxomicin and 29.0% for vancomycin] and –10.3% [data not reported due to CMS policy restricting cell sizes <11] in the recurrent CDI episodes) that was in favor of fidaxomicin but did not reach statistical significance, possibly due to small sample sizes.

also in 111,027 other papers